Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS
Status:
Completed
Trial end date:
2019-08-29
Target enrollment:
Participant gender:
Summary
This study was done to compare the safety and efficacy of three combination treatments for
Kaposi's Sarcoma (KS) and AIDS:
1. Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
(EFV/FTC/TDF) (ET+ART),
2. Bleomycin and Vincristine (BV) plus co-formulated EFV/FTC/TDF (BV+ART),
3. Paclitaxel (PTX) plus co-formulated EFV/FTC/TDF (PTX+ART).
Phase:
Phase 3
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborators:
AIDS Malignancy Consortium National Cancer Institute (NCI) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Dental and Craniofacial Research (NIDCR)
Treatments:
Bleomycin Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Etoposide Paclitaxel Tenofovir Vincristine